linjc16/ctgov huggingface dataset:
The Usefulness of HyperQ Recordings for the Early Diagnosis of Acute Coronary Syndrome in Patients Presenting With Chest Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to assess the usefulness of high Frequency mid-QRS analysis in identifying the ischemic origin of patients presenting to the Emergency Room (ER)with Chest pain.

Detailed Description
-----------------
Introduction: Chest pain is the leading cause of urgent admission to the Emergency Department (ED) in western countries.Acute Coronary Syndrome(ACS) continues to be among the most difficult to predict or diagnose. Misdiagnoses may lead to discharge of patients with ACS, who should have been admitted as well as costly unnecessary hospitalizations of patients who do not have ACS. Objectives: To evaluate the usefulness of High Frequency mid-QRS analysis in identifying the ischemic patients out of all patients presenting to the Emergency Room (ER) with chest pain. Comparisons: A continuous High Frequency Mid-QRS recording will be performed using the HyperQ System (BSP Ltd.) and compared to clinical, electrophysiologic and laboratory results. The golden standards used to compare the methods will be either CT-Angio, Echocardiography or Cardiac SPECT. A follow-up inquiry will be performed after 3 months and Coronary Angiography results will be sought and compared as well.

Official Title
-----------------
The Usefulness of HyperQ Recordings for the Early Diagnosis of Acute Coronary Syndrome in Patients Presenting With Chest Pain

Conditions
-----------------
Acute Coronary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Patients with chest pain, with possible ACS. Patients admitted to the 'chest pain unit' Chest pain appeared within 24 hours prior to admission to the 'chest pain unit' No history of trauma or any other evident medical cause of chest pain Signed an Informed Consent Exclusion Criteria: Implanted pacemaker or defibrillator History of trauma or other evident medical cause of chest pain Patients admitted to Intensive Cardiac Care Unit or intermediate Cardiac Care Unit Patients discharged from the ER Patients with Bundle-Branch-Block or other intra-ventricular delay of more than 120 mSec

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute, Coronary, Syndrome, HyperQ, High, Frequency, ECG, chest, pain
Effect of Plasma Rich in Growth Factors on Semen Quality

Study Overview
=================
Brief Summary
-----------------
The hypothesis is growing semen samples with plasma rich in growth factors (PRGF), because it could improve sperm motility in patients subsidiary TRA, ultimately improving pregnancy rates.

Detailed Description
-----------------
Platelet growth factors are a group of proteins involved in cellular communication modifying biological responses. Obtaining plasma rich in growth factors is already widespread and simple protocol technique that is being used in various areas of medicine with superb results. Described many of the growth factors present in the PRGF are related to sperm parameters, especially motility The described effects have been studied in mammalian and each growth factor individually. PRGF contains a pool of growth factors and therefore be interesting to analyze their effect on various sperm parameters. One of those parameters is very important for fertilization sperm motility, since the lack of it will prevent displacement by the cervix to meet the egg in the fallopian tube.

Official Title
-----------------
Effect of Plasma Rich in Growth Factors (PRGF) on Semen Quality

Conditions
-----------------
Vascular Endothelial Growth Factor Overexpression

Intervention / Treatment
-----------------
* Biological: PRGF in candidates for sperm donors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-35 years more than 5 million sperm per milliliter Exclusion Criteria: Not having genetic and infectious diseases Do not suffer mental illness Have a family study determined that there is no risk of hereditary diseases There have fathered more than 6 children in the country

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PRGF in candidates for sperm donors<br>Prospective study of 58 candidates for sperm donors clinic IVI Bilbao. | Biological: PRGF in candidates for sperm donors<br>* PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the percentage of motile sperm adding PRGF versus those samples that growth factors were not added | Within concerted donor visits in IVI Bilbao will be held: Removing Blood 9 mL of blood to obtain plasma rich in factors growth Seminogram to analyze all semen parameters according to the criteria of the WHO (2010), paying particular attention to sperm motility. Sperm vitality will be analyzed before and after treatment with PRGF. PRGF application on the seminal aliquots will be conducted at different concentrations assessing sperm motility. | 6 months |
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome

Study Overview
=================
Brief Summary
-----------------
Developing a molecular genetic test that can identify prognostic factors which can predict response to treatment, and to contribute to the establishment of future therapeutic strategies base on prognostic factors by undergoing peripheral blood and bone marrow examination of Myelodysplastic Syndrome (MDS) patients at diagnosis and relapse.

Conditions
-----------------
Myelodysplastic Syndrome

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: MDS diagnosed by bone marrow aspiration and biopsy at Severance Hospital. Male and Female over 16 years of age. ③ Written consent of the patient to participate in the cohort ④ Deaths during the study period are waiver of consent Exclusion Criteria: ① Refusal or trouble understanding the written consent

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of patients with MDS to examine new prognostic factors |  | 10 years |
Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices

Study Overview
=================
Brief Summary
-----------------
Over the past year smartphones have developed from a niche product to a commoditized product and are now squeezing classic mobile phones out of market. According to a survey a quarter of the German population is making use of a smartphone at present. An interference between smartphones and the functionality of pacemakers or implantable defibrillators is rather unlikely but cannot entirely be excluded. A systematic study regarding a possible interference between smartphones and modern pacemaker- and ICD-system with a better shielding against external influence has not taken place so far. In this study the investigators intend to investigate any interference between different smartphones produced by different manufacturers and diverse cardiovascular implanted electronic devices.

Official Title
-----------------
Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices

Conditions
-----------------
Recipients of Implantable Pacemakers or Defibrillators

Intervention / Treatment
-----------------
* Drug: Pacemaker and defibrillator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of an implantable pacemaker or defibrillator Exclusion Criteria: Lead malfunction which can not reprogrammed Battery depletion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pacemakers and defibrillators<br> | Drug: Pacemaker and defibrillator<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interference of smartphones with cardiac implantable electronic devices | Interference testing will be performed during routine follow-up of pacemakers or defibrillators and potential interference will be recorded by ECG. | acute study (no follow-up) |
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fasting conditions.

Official Title
-----------------
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions

Conditions
-----------------
Herpes Zoster, Shingles, Genital Herpes

Intervention / Treatment
-----------------
* Drug: Valacyclovir Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to valacyclovir hydrochloride or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Valacyclovir Hydrochloride|1000 mg caplet|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | 8 days |
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension

Conditions
-----------------
Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: brimonidine/timolol fixed combination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of glaucoma or ocular hypertension in both eyes Patient requires IOP-lowering in both eyes Exclusion Criteria: Uncontrolled medical conditions Contraindication to beta-andrenoceptor antagonist or brimonidine therapy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: brimonidine/timolol fixed combination|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP |  |  |
OptiSense™ Performance in Detecting Atrial Episodes

Study Overview
=================
Brief Summary
-----------------
The SENSE-AF study aims to determine the performance of the OptiSense lead in sensing fine episodes of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) and rejecting Far-Field R Wave (FFRW). The performance of the lead will be measured as a difference in device-determined time in AT/AF and surface-ECG determined time in AT/AF. This measurement will be compared to the control group which will be randomized to receive SJM's Tendril™ RA leads.

Official Title
-----------------
OptiSense Performance in Detecting Atrial Episodes in CRMD Device Patient Population

Conditions
-----------------
Tachyarrhythmias, Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: OptiSense Lead
* Device: Tendril Lead


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who meets current ICD or CRT-D implant indications and receive a St. Jude Medical ICD/CRT-D Patients who will receive a new St. Jude Medical OptiSense or Tendril RA lead as part of their device implant Exclusion Criteria: Patients with a history of Permanent or Persistent AF Patient's life expectancy is less than 12 months. Patient is pregnant. Patient's age at enrollment is less than 18 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1. Control<br>Patients will receive the Tendril (wide-spaced) lead as part of their ICD implant | Device: Tendril Lead<br>* The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead.<br>|
| 2. Experimental<br>Patients will receive the OptiSense (narrow-spaced) lead as part of their ICD implant | Device: OptiSense Lead<br>* The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint of the study is the difference in duration between the device-determined time in AF (Device Duration) and the ECG-determined time in AF (ECG Duration). |  | 3 months post-implant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ICD, Tachyarrhythmias, Atrial Fibrillation, Patients who meets current ICD or CRT-D implant indications
Colorectal Polyp Resection Adequacy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the best way to ensure that polyps are completely removed by evaluating the borders of the removed polyp. If a polyp is found that meets the size requirements for the study, the investigators will take extra biopsies of the margin to determine if there is any abnormal tissue or cancer at these borders.

Official Title
-----------------
Determining True Colorectal Polyp Resection Adequacy: Correlation of Endoscopic Margins With Histopathologic Margins

Conditions
-----------------
Polyp Resection Adequacy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 40-80 Exclusion Criteria: Coagulopathy (international normalized ratio >2) Inflammatory bowel disease or other active colitides Polyps of index colonoscopy that were felt not to be completely resected or pedunculated Familial adenomatous polyposis or hereditary polyposis Potential hereditary cancer syndrome (Lynch Syndrome)

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incomplete resection rates in polyps from Group 1 (clear margins) versus Group 2 (positive margins). | Define the frequency of free margins versus margins that have dysplasia to the cautery site in snare polypectomy. A free margin is defined as uninvolved or normal mucosa extending to the cautery margin at the polypectomy stalk. | Between 3-6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal Cancer Screening, Colon Cancer Screening, Polyps, Colonoscopy
Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the prevalence of esophageal pathology in asymptomatic patients with a history of head and neck cancer.

Detailed Description
-----------------
There are certain factors (i.e. alcohol, tobacco, decreased saliva production from radiation) that predispose patients with a history of head and neck cancer to have esophageal disease. Often, in the initial stages of the disease, patients do not have symptoms. However, the early detection of precancerous lesions or small cancers improves patients' chances of being cured. There is no direct data supporting the practice of screening patients with a history of head and neck cancer after treatment for esophageal disease if they are not experiencing symptoms. However, many argue that screening endoscopy is justified in high risk patients to detect early esophageal cancer or dysplasia at a curable state. We are, therefore, performing this study to determine the value of endoscopic screening of the esophagus after treatment for head and neck cancer in patients without symptoms.

Official Title
-----------------
Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?

Conditions
-----------------
Esophageal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Head and neck cancer patients that are six months post treatment and asymptomatic for esophageal disease. Exclusion Criteria: None if meets the inclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Those six months post treatment for head and neck cancer. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early detection of esophageal cancer or dysplasia in patients without symptoms, after treating their primary cancer, may improve their chances of being cured of a secondary disease. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
esophageal cancer, head and neck cancer, dysplasia
Virtual Coronary Intervention and Non-invasive Fractional Flow Reserve (FFR)

Study Overview
=================
Brief Summary
-----------------
The investigators examined the feasibility of treatment planning using virtual coronary revascularization and fractional flow reserve (FFR) CT before the invasive procedures.

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Significant stenosis at CT angiography Normal ejection fraction on echocardiography Informed consented patient Exclusion Criteria: Total occlusion and collateral flow to target vessel AV conduction abnormality Left ventricular hypertrophy Significant valvular heart or primary myocardial disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary artery disease, CT, Computational flow dynamics
To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets

Study Overview
=================
Brief Summary
-----------------
To demonstrate the relative bioavailability of Desipramine Hydrochloride tablets.

Official Title
-----------------
Bioavailability of Desipramine Hydrochloride Tablets

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Drug: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
* Drug: Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories) | Drug: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)<br> <br> |
| Active Comparator: 2<br>Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.) | Drug: Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence based on AUC and Cmax |  | 22 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antidepressant